Q3-osavuosiraportti
25 päivää sitten‧1 t 9 min
3,75 DKK/osake
Viimeisin osinko
3,75 %Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
4 026 542
Myynti
Määrä
4 112 396
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 48 | - | - | ||
| 873 | - | - | ||
| 50 | - | - | ||
| 873 | - | - | ||
| 917 | - | - |
Ylin
321,45VWAP
Alin
309,3VaihtoMäärä
2 509,5 7 922 266
VWAP
Ylin
321,45Alin
309,3VaihtoMäärä
2 509,5 7 922 266
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Ylimääräinen yhtiökokous | 14.11. | |
| 2025 Q3-osavuosiraportti | 5.11. | |
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Q2-osavuosiraportti | 6.8. | |
| 2025 Q1-osavuosiraportti | 7.5. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·7 t sittenAre you going to sell your shares that are at a loss? And buy them back again afterwards. To realize the loss? Thanks in advance
·48 min sitten · MuokattuI have previously used the strategy of selling a position in another stock at a loss and got 100,000 kroner in tax savings. With that money, I could buy even more shares back than I originally sold and now have more shares to get a return on. Quite ingenious to get the tax authorities to partially finance investments.
·15 t sittenJust the wegovy brand makes novos's pill significantly more relevant for consumers. Anyone know anything about a possible sNDA after cagrisema submisson in q1 2026, possibly at 7.2 mg like with wegovy? It really seems like they follow a certain pattern when they set their doses, perhaps? Much indicates that cagrisema would have reached 25 % weight loss if not more if they had had more time. They probably said something about most not having reached the highest dose and even those who had reached it had not done so until late in the study.
·19 t sittenA number of institutional investors and hedge funds have recently made changes to their positions in the industry. Revolve Wealth Partners LLC increased its stake in Novo Nordisk A/S by 8,7 % in the 4th quarter. Revolve Wealth Partners LLC now owns 2.490 shares in the company worth $214.000 after purchasing an additional 200 shares in the latest quarter. Zurcher Kantonalbank Zürich Cantonalbank purchased a new position in shares of Novo Nordisk A/S in the first quarter worth approximately 41.000 dollars. GSA Capital Partners LLP purchased a new stake in Novo Nordisk A/S in the first quarter worth approximately 923.000 dollars. Banque Cantonale Vaudoise purchased a new stake in Novo Nordisk A/S in the first quarter worth 1.013.000 dollars. Finally, XTX Topco Ltd purchased a new stake in Novo Nordisk A/S in the first quarter worth 706.000 dollars. Hedge funds and other institutional investors own 11,54 % of the company's shares. found on proinvester novo nordisk·18 t sittenYes, that's just how it is. Some buy and some sell....
·1 päivä sittenHad we been without (which we weren't, of course) compounders in 2025, that took 50 percent of sales, would we have experienced a fall in the share price at all? And would we then have had all these disaster talks about the future?
·22 t sittenNN had publicly foreseen semaglutid’s potential (Krogsgaard, Medwatch, 6/12-2019), but failed to prepare the necessary production capacity. They wanted to see the demand first before taking the risk. That is an extremely conservative attitude, an aversion to risk, which Lilly exploited. Aversion to risk = toxic culture.- ·1 päivä sittenIn addition to an excellent podcast here on the site, I would recommend listening to the latest from Børsen Investor.
·23 t sittenCan you give a link can not find it
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
25 päivää sitten‧1 t 9 min
3,75 DKK/osake
Viimeisin osinko
3,75 %Tuotto/v
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7 t sittenAre you going to sell your shares that are at a loss? And buy them back again afterwards. To realize the loss? Thanks in advance·48 min sitten · MuokattuI have previously used the strategy of selling a position in another stock at a loss and got 100,000 kroner in tax savings. With that money, I could buy even more shares back than I originally sold and now have more shares to get a return on. Quite ingenious to get the tax authorities to partially finance investments.
- ·15 t sittenJust the wegovy brand makes novos's pill significantly more relevant for consumers. Anyone know anything about a possible sNDA after cagrisema submisson in q1 2026, possibly at 7.2 mg like with wegovy? It really seems like they follow a certain pattern when they set their doses, perhaps? Much indicates that cagrisema would have reached 25 % weight loss if not more if they had had more time. They probably said something about most not having reached the highest dose and even those who had reached it had not done so until late in the study.
- ·19 t sittenA number of institutional investors and hedge funds have recently made changes to their positions in the industry. Revolve Wealth Partners LLC increased its stake in Novo Nordisk A/S by 8,7 % in the 4th quarter. Revolve Wealth Partners LLC now owns 2.490 shares in the company worth $214.000 after purchasing an additional 200 shares in the latest quarter. Zurcher Kantonalbank Zürich Cantonalbank purchased a new position in shares of Novo Nordisk A/S in the first quarter worth approximately 41.000 dollars. GSA Capital Partners LLP purchased a new stake in Novo Nordisk A/S in the first quarter worth approximately 923.000 dollars. Banque Cantonale Vaudoise purchased a new stake in Novo Nordisk A/S in the first quarter worth 1.013.000 dollars. Finally, XTX Topco Ltd purchased a new stake in Novo Nordisk A/S in the first quarter worth 706.000 dollars. Hedge funds and other institutional investors own 11,54 % of the company's shares. found on proinvester novo nordisk·18 t sittenYes, that's just how it is. Some buy and some sell....
- ·1 päivä sittenHad we been without (which we weren't, of course) compounders in 2025, that took 50 percent of sales, would we have experienced a fall in the share price at all? And would we then have had all these disaster talks about the future?·22 t sittenNN had publicly foreseen semaglutid’s potential (Krogsgaard, Medwatch, 6/12-2019), but failed to prepare the necessary production capacity. They wanted to see the demand first before taking the risk. That is an extremely conservative attitude, an aversion to risk, which Lilly exploited. Aversion to risk = toxic culture.
- ·1 päivä sittenIn addition to an excellent podcast here on the site, I would recommend listening to the latest from Børsen Investor.·23 t sittenCan you give a link can not find it
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
4 026 542
Myynti
Määrä
4 112 396
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 48 | - | - | ||
| 873 | - | - | ||
| 50 | - | - | ||
| 873 | - | - | ||
| 917 | - | - |
Ylin
321,45VWAP
Alin
309,3VaihtoMäärä
2 509,5 7 922 266
VWAP
Ylin
321,45Alin
309,3VaihtoMäärä
2 509,5 7 922 266
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Ylimääräinen yhtiökokous | 14.11. | |
| 2025 Q3-osavuosiraportti | 5.11. | |
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Q2-osavuosiraportti | 6.8. | |
| 2025 Q1-osavuosiraportti | 7.5. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
25 päivää sitten‧1 t 9 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Ylimääräinen yhtiökokous | 14.11. | |
| 2025 Q3-osavuosiraportti | 5.11. | |
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Q2-osavuosiraportti | 6.8. | |
| 2025 Q1-osavuosiraportti | 7.5. |
Datan lähde: Millistream, Quartr
3,75 DKK/osake
Viimeisin osinko
3,75 %Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7 t sittenAre you going to sell your shares that are at a loss? And buy them back again afterwards. To realize the loss? Thanks in advance·48 min sitten · MuokattuI have previously used the strategy of selling a position in another stock at a loss and got 100,000 kroner in tax savings. With that money, I could buy even more shares back than I originally sold and now have more shares to get a return on. Quite ingenious to get the tax authorities to partially finance investments.
- ·15 t sittenJust the wegovy brand makes novos's pill significantly more relevant for consumers. Anyone know anything about a possible sNDA after cagrisema submisson in q1 2026, possibly at 7.2 mg like with wegovy? It really seems like they follow a certain pattern when they set their doses, perhaps? Much indicates that cagrisema would have reached 25 % weight loss if not more if they had had more time. They probably said something about most not having reached the highest dose and even those who had reached it had not done so until late in the study.
- ·19 t sittenA number of institutional investors and hedge funds have recently made changes to their positions in the industry. Revolve Wealth Partners LLC increased its stake in Novo Nordisk A/S by 8,7 % in the 4th quarter. Revolve Wealth Partners LLC now owns 2.490 shares in the company worth $214.000 after purchasing an additional 200 shares in the latest quarter. Zurcher Kantonalbank Zürich Cantonalbank purchased a new position in shares of Novo Nordisk A/S in the first quarter worth approximately 41.000 dollars. GSA Capital Partners LLP purchased a new stake in Novo Nordisk A/S in the first quarter worth approximately 923.000 dollars. Banque Cantonale Vaudoise purchased a new stake in Novo Nordisk A/S in the first quarter worth 1.013.000 dollars. Finally, XTX Topco Ltd purchased a new stake in Novo Nordisk A/S in the first quarter worth 706.000 dollars. Hedge funds and other institutional investors own 11,54 % of the company's shares. found on proinvester novo nordisk·18 t sittenYes, that's just how it is. Some buy and some sell....
- ·1 päivä sittenHad we been without (which we weren't, of course) compounders in 2025, that took 50 percent of sales, would we have experienced a fall in the share price at all? And would we then have had all these disaster talks about the future?·22 t sittenNN had publicly foreseen semaglutid’s potential (Krogsgaard, Medwatch, 6/12-2019), but failed to prepare the necessary production capacity. They wanted to see the demand first before taking the risk. That is an extremely conservative attitude, an aversion to risk, which Lilly exploited. Aversion to risk = toxic culture.
- ·1 päivä sittenIn addition to an excellent podcast here on the site, I would recommend listening to the latest from Børsen Investor.·23 t sittenCan you give a link can not find it
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
4 026 542
Myynti
Määrä
4 112 396
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 48 | - | - | ||
| 873 | - | - | ||
| 50 | - | - | ||
| 873 | - | - | ||
| 917 | - | - |
Ylin
321,45VWAP
Alin
309,3VaihtoMäärä
2 509,5 7 922 266
VWAP
Ylin
321,45Alin
309,3VaihtoMäärä
2 509,5 7 922 266
Välittäjätilasto
Dataa ei löytynyt